Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis

Victoria T. Brown, Dana Drzayich Antol, Patrick N. Racsa, Melea A. Ward, Jarushka Naidoo

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs. Methods: irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥ 1 dose of therapy between 1 September 2014 and 28 February 2018. Results: Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in patients with irAEs. Conclusion: These data underscore the needs for tailored irAE diagnostic and management pathways.

Original languageEnglish (US)
Pages (from-to)789-796
Number of pages8
JournalCancer Investigation
Volume39
Issue number10
DOIs
StatePublished - 2021

Keywords

  • cancer in the elderly
  • Therapy
  • treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis'. Together they form a unique fingerprint.

Cite this